Amgen Urges Adoption Of Balanced Policies For Biosimilars
Chad Pettit Discusses Amgen’s Unique Perspective On Biosimilars
A balanced policy environment that can support biosimilar competition is needed to allow the drugs to flourish in the US, says Amgen’s executive director of marketing and global biosimilars commercial lead Chad Pettit.
You may also be interested in...
A bipartisan group of senators has written to the US Patent and Trademark Office, urging it to tackle the impact of patent thickets on the generic and biosimilar drug industries.
At an eventful time for US biosimilars, a fresh wave of players entering the market is expected to both increase competition and broaden access, AmerisourceBergen’s senior vice president for global emerging therapies and channel strategy Beth McMahon tells Generics Bulletin.
Amgen has added a further treatment for inflammatory diseases to its vast portfolio, with the FDA approving its rituximab biosimilar Riabni for rheumatoid arthritis.